12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Company News  |  Deals

arGEN-X, Shire deal

Shire partnered with arGEN-X to discover and develop mAbs against multiple undisclosed targets to treat rare genetic diseases. arGEN-X will use its SIMPLE Antibody platform to isolate and characterize...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >